Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer

A pharmaceutical combination comprising a compound represented by the structure of formula (I), or salts or hydrates thereof, in combination with an anti-programmed cell death protein 1 (PD-1) antibody, an anti-programmed cell death protein 1 ligand (PD-L1) antibody, or a combination thereof:

• wherein:
• R1, R2, R3, R5, and R6 are each independently selected from the group consisting of H, halogen, haloalkyl, and OR16, wherein R16is H or C1-C4 alkyl;
• R4 is H or CN;
• and
• R7 is H or C1-C4 alkyl.

A pharmaceutical combination comprising a compound represented by the structure of formula (II), or salts or hydrates thereof, in combination with an anti-programmed cell death protein 1 (PD-1) antibody, an anti-programmed cell death protein 1 ligand (PD-L1) antibody, or a combination thereof:

• wherein:
• A is H or CN;
• X1, X2, X3, and X4 are each independently selected from H, halogen, C1-C4 alkyl, haloalkyl, and OR1, wherein R1 is H or C1-C4 alkyl;
• and
• X5 is H or C1-C4 alkyl.